IRIS - Res&Arch Institutional Research Information System - Research & Archive

SCHIAROLI, ELISABETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.560
AS - Asia 2.760
EU - Europa 1.983
SA - Sud America 506
Continente sconosciuto - Info sul continente non disponibili 353
AF - Africa 87
OC - Oceania 5
Totale 9.254
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.431
SG - Singapore 1.388
IT - Italia 501
BR - Brasile 386
CN - Cina 379
IE - Irlanda 379
HK - Hong Kong 363
RU - Federazione Russa 325
VN - Vietnam 188
DE - Germania 148
FR - Francia 147
BD - Bangladesh 97
GB - Regno Unito 96
KR - Corea 75
FI - Finlandia 72
CA - Canada 67
UA - Ucraina 66
IN - India 51
SE - Svezia 51
AR - Argentina 40
AT - Austria 40
EE - Estonia 36
TR - Turchia 31
JP - Giappone 26
PL - Polonia 26
MX - Messico 23
IQ - Iraq 22
NL - Olanda 22
ZA - Sudafrica 22
ID - Indonesia 20
VE - Venezuela 18
ES - Italia 17
UZ - Uzbekistan 17
EC - Ecuador 16
PH - Filippine 16
PK - Pakistan 15
BE - Belgio 13
CO - Colombia 12
CH - Svizzera 11
EG - Egitto 11
AE - Emirati Arabi Uniti 10
MA - Marocco 10
MY - Malesia 10
PY - Paraguay 10
CL - Cile 9
JO - Giordania 9
KE - Kenya 9
SA - Arabia Saudita 8
DZ - Algeria 7
HN - Honduras 7
LT - Lituania 7
NI - Nicaragua 7
PE - Perù 7
BO - Bolivia 6
CR - Costa Rica 6
ET - Etiopia 6
IL - Israele 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
CZ - Repubblica Ceca 4
GR - Grecia 4
JM - Giamaica 4
PA - Panama 4
AO - Angola 3
AU - Australia 3
IR - Iran 3
LB - Libano 3
LY - Libia 3
RO - Romania 3
SN - Senegal 3
SY - Repubblica araba siriana 3
BY - Bielorussia 2
CI - Costa d'Avorio 2
DK - Danimarca 2
GA - Gabon 2
KZ - Kazakistan 2
MD - Moldavia 2
NP - Nepal 2
PS - Palestinian Territory 2
PT - Portogallo 2
QA - Qatar 2
SV - El Salvador 2
TH - Thailandia 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BT - Bhutan 1
BW - Botswana 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EU - Europa 1
GH - Ghana 1
GT - Guatemala 1
HR - Croazia 1
KG - Kirghizistan 1
KH - Cambogia 1
LU - Lussemburgo 1
Totale 8.888
Salva come PNG Salva come JPEG
Città #
Singapore 1.002
San Jose 501
Dublin 379
Hong Kong 359
Chandler 318
Ashburn 228
Perugia 185
San Mateo 169
Santa Clara 148
Boardman 125
Moscow 124
Altamura 116
Lauterbourg 99
Dearborn 94
Los Angeles 87
Medford 83
Princeton 83
Lawrence 80
New York 79
Beijing 78
Seoul 74
The Dalles 68
Munich 59
Wilmington 57
Ho Chi Minh City 56
Ann Arbor 55
Andover 51
Columbus 50
São Paulo 41
Dong Ket 39
Hanoi 36
Piscataway 35
Falls Church 30
Tokyo 26
Des Moines 25
Nuremberg 24
Montreal 23
Dallas 22
Helsinki 22
Redmond 22
Rio de Janeiro 22
Frankfurt am Main 21
Hefei 20
Turku 19
Buffalo 18
Orem 18
Florence 17
Houston 17
Saint Petersburg 17
Amsterdam 16
Chicago 16
Rome 16
Vienna 16
Warsaw 15
Norwalk 14
San Paolo di Civitate 14
Tashkent 14
Milan 13
Brooklyn 12
Brussels 12
Jacksonville 12
Poplar 12
Toronto 12
Atlanta 11
London 11
Mexico City 11
Chennai 10
Johannesburg 10
Manchester 10
Woodbridge 10
Amman 9
Ankara 9
Dhaka 9
Ottawa 9
Padova 9
Phoenix 9
San Francisco 9
Bastia umbra 8
Boston 8
Brasília 8
Denver 8
Falkenstein 8
Baghdad 7
Belo Horizonte 7
Council Bluffs 7
Curitiba 7
Jakarta 7
Naples 7
Redwood City 7
Shanghai 7
Addis Ababa 6
Bologna 6
Caracas 6
Charlotte 6
Espoo 6
Guangzhou 6
Guayaquil 6
Haiphong 6
Izmir 6
Lappeenranta 6
Totale 5.807
Salva come PNG Salva come JPEG
Nome #
NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial 172
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 135
Effect of aspirin treatment on abacavir-associated platelet hyperreactivity in HIV-infected patients 135
Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. 123
Leflunomide protects against dyslipidemia development induced by ritonavir in mice 122
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 121
Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected 120
Impact of SARS-CoV-2 Omicron variants on serum neutralization in a cohort of healthcare workers vaccinated with BNT162b2 116
A nutraceutical combination targeting dyslipidemia and subclinical inflammation in HIV patients on stable antiretroviral therapy 116
Partial achievement of the 90-90-90 UNAIDS target in a cohort of HIV infected patients from Central Italy 116
Effects of antiretroviral therapy on lipid and immunovirological profile: Focus on proprotein convertase subtilisin/kexin 9 112
A first update on mapping the human genetic architecture of COVID-19 111
Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: A Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians 109
Mapping the human genetic architecture of COVID-19 108
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 107
Bile acid activated receptors are targets for regulation of integrity of gastrointestinal mucosa 105
Smoking Habits in Human Immunodeficiency Virus-Infected People from Italy: A Cross-Sectional Analysis of the STOPSHIV Cohort 105
Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality 104
Biochemical markers of bone turnover and calcium dietary intake evaluation in HIV-infected patients 103
Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus 103
Predictive risk factors for worse outcomes in COVID-19 patients with different clinical features at baseline 103
Low brachial artery flow-mediated dilation predicts worse prognosis in hospitalized patients with covid-19 102
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry 101
Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria 100
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 100
Role of nucleocapsid protein antigen detection for safe end of isolation of sars-cov-2 infected patients with long persistence of viral rna in respiratory samples 99
Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study 98
Seroprevalence of anti-SARS-CoV2 antibodies in umbrian persons living with HIV 97
Clusterization of co-morbidities and multi-morbidities among persons living with HIV: A cross-sectional study 96
Comorbidities, cardiovascular therapies, and COVID-19 mortality: A nationwide, italian observational study (ItaliCO) 96
Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism 95
An explainable model of host genetic interactions linked to COVID-19 severity 94
The HIV Matrix Protein p17 subverts Nuclear Receptors Expression and induces a STAT1-Dependent Proinflammatory Phenotype in Monocytes 93
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 93
Effects of antiretroviral therapy on proprotein convertase subtilisin/kexin 9: focus on lipids, inflammation and immunovirological parameters 92
The association between neutrophil to lymphocyte ratio and endothelial dysfunction in people living with HIV on stable antiretroviral therapy 92
Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-γ-dependent manner. 91
Percutaneous vertebroplasty improves pain control and quality of life in patients suffering from back pain: A single center experience 91
Reactivation of hepatitis B virus replication due to cytotoxic therapy:a five-year prospective study 90
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort 90
Management of Hepatitis B Virus Reactivation in Patients with Hematological Malignancies Treated with Chemotherapy. 88
Bone-turnover markers in white HIV-infected patiens treated with or without TDF-containg regimens 88
Genetic mechanisms of critical illness in COVID-19 88
Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients 88
Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH) 87
Whole-genome sequencing reveals host factors underlying critical COVID-19 87
BNT162b2 Elicited an Efficient Humoral Response Against Different Strains of SARS-CoV-2 in People Living with HIV 87
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 87
The HIV Matrix Protein p17 promotes the Activation of human hepatic stellate cells through interactions with CXCR2 and Syndecan-2 86
Carbapenemase-producing Enterobacteriaceae isolates resistant to last-line antibiotics in an Italian general hospital. 86
Early treatment with bamlanivimab alone does not prevent COVID-19 hospitalization and its post-acute sequelae. A real experience in Umbria, Italy 86
Prevalence of smoking and nicotine dependence in HIV patients, the project STOPS HIV from Italy 85
The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro 83
Stabilization of the Dimeric State of SARS-CoV-2 Main Protease by GC376 and Nirmatrelvir 83
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study 82
Lingual tubercolosis: a rare disease in western countries 81
Nelfinavir: An Old Ally in the COVID-19 Fight? 79
Is the rate of virological failure to cART continuing to decline in recent calendar years? 79
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 77
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 77
Tixagevimab/Cilgavimab: Still a Valid Prophylaxis against COVID-19 New Variants? 76
Diagnosis of Nocardia paucivorans central nervous system infection by DNA sequencing from paraffin-embedded tissue 76
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 76
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 75
Predictive factors and prevalence of microalbuminuria in HIV-infected patients: A cross-sectional analysis 73
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort 73
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 72
Epidemiology and Microbiology of Skin and Soft Tissue Infections: Preliminary Results of a National Registry 72
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 71
The HIV matrix protein p17 induces hepatic lipid accumulation via modulation of nuclear receptor transcriptoma 69
Meningitis with cranial polyneuritis and cavernous sinus thrombosis by Borrelia crocidurae: First autochthonous case in Europe 69
Protective role of a tmprss2 variant on severe covid-19 outcome in young males and elderly women 69
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 67
Synergistic Activity of Remdesivir–Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report 66
Role of Maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced 66
Effect of directly acting antivirals for hepatitis C virus infection on proprotein convertase subtilisin/kexin type 9 level 66
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 65
HIV-1 infection is associated with changes in nuclear receptor transcriptome, pro-inflammatory and lipid profile of monocytes 64
Tedizolid-Rifampicin Combination Prevents Rifampicin-Resistance on in vitro Model of Staphylococcus aureus Mature Biofilm 63
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 62
Management of Meningitis Caused by Multi Drug-Resistant Acinetobacter Baumannii: Clinical, Microbiological and Pharmacokinetic Results in a Patient Treated with Colistin Methanesulfonate 62
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 62
Elevated serum uric acid levels are associated with endothelial dysfunction in HIV patients receiving highly-active antiretroviral therapy 62
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART 62
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting 62
HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients 62
Gangrenous Chickenpox with Atypical Clinical and Histopathological Findings. 61
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 61
The hope and hype of ellagic acid and urolithins as ligands of SARS-CoV-2 Nsp5 and inhibitors of viral replication 60
Epidemiology, aetiology and treatment of skin and soft tissue infections: final report of a prospective multicentre national registry 60
Transgender people living with HIV: characteristics and comparison to homosexual and heterosexual cisgender patients in two Italian teaching hospitals 58
Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study 57
Urinary albumin-to-creatinine ratio is associated with endothelial dysfunction in HIV-infected patients receiving antiretroviral therapy 56
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 56
Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort 55
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study 55
Role of pretreatment variables on plasma HIV RNA value at the sixth month of antiretroviral therapy including all first line drugs in HIV naïve patients: A path analysis approach 54
Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies 53
Clinical and molecular characterization of COVID-19 hospitalized patients 51
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 51
Totale 8.490
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.868
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.868
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022634 0 120 5 12 27 17 14 179 30 47 94 89
2022/20231.260 88 269 17 109 92 106 9 39 469 0 36 26
2023/2024512 27 71 20 8 5 3 134 4 28 29 102 81
2024/20251.847 26 132 65 63 212 85 160 91 415 137 291 170
2025/20263.886 249 228 245 478 470 305 692 212 485 278 146 98
2026/2027333 200 133 0 0 0 0 0 0 0 0 0 0
Totale 9.254